Synapse - Shanu Modi

Search Within

Shanu Modi

Results (265)

Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Phase 1 dose-escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2+ metastatic breast cancer

Meeting Abstract

Modi, S.; Ismail-Khan, R.; Munster, P.; Lucas, M.; Galluppi, G. R.; Tangri, S.; Chen, Y.; Yamashita, M.; Storgard, C. M.; Moulder, S.
Cancer Research (2010)

Fulltext@MSK | Save

A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen

Meeting Abstract

Krop, I. E.; Modi, S.; Elias, A.; LoRusso, P.; Choi, Y. J.; Lu, M.
Cancer Research (2010)

Fulltext@MSK | Save

Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen

Meeting Abstract

Lu, D.; Krop, I.; Modi, S.; Elias, A.; LoRusso, P.; Huang, J.; Lu, M.; Girish, S.
Cancer Research (2010)

Fulltext@MSK | Save

A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
Cancer Research (2010)

Fulltext@MSK | Save

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

Journal Article

Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, S.; Tibbitts, J.; Yi, J. H.; Sliwkowski, M. X.; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results

Journal Article

Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K.
Clinical Breast Cancer (2010)

Fulltext@MSK | Save

Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab

Meeting Abstract

Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+breast cancer

Meeting Abstract

Krop, I. E.; Mita, M.; Burris, H. A.; Birkner, M.; Girish, S.; Tibbitts, J.; Holden, S. N.; Lutzker, S. G.; Modi, S.
Cancer Research (2009)

Fulltext@MSK | Save

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results

Meeting Abstract

Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
Cancer Research (2009)

Fulltext@MSK | Save